Clinical Trial Update: A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs [Phase 2]

View source ↗

Summary

Phase 2 trial assessing intermittent dosing of imatinib in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors (GISTs) has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors (GISTs) | Phase 2 | Status: COMPLETED